Cellebrite DI
CLBT Mid CapTechnology · Software - Infrastructure
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Cellebrite DI en bref
Cellebrite DI (CLBT) is currently trading at 12,82 € with a market capitalization of 3,2 Md €. The trailing P/E ratio stands at 52.68x, with a forward P/E of 22.31x. The 52-week range spans from 9,58 € to 17,36 €; the current price is 26.2% below the yearly high. Year-over-year revenue growth stands at +19.3%. The net profit margin stands at 14.48%.
💰 Dividende
Cellebrite DI currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
7 analystes évaluent Cellebrite DI (CLBT) au consensus : None. L'objectif de cours moyen est de 18,25 €, soit un potentiel de +42.37% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,04 € à 24,33 €.
Cellebrite DI : la thèse d'investissement en détail
Cellebrite DI (CLBT) operates in the Technology — specifically Software - Infrastructure — and is headquartered in Israel. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 19.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 83.86%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 40.58x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 22.31x is meaningfully below the trailing 52.68x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 42.37% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (16.44% ROE)
- Marge brute élevée de 83.86% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 4.47)
- Free cash flow positif
- –Multiple de valorisation élevé (P/E 52.68x)
- –Actuellement jugée surévaluée
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (5.02%).
Trading Data
Related Stocks in the Same Sector
More Technologie stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Cellebrite DI?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news